This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Procedures, Other  • Facial Plastic Surgery  • Cosmetic Surgery/ Procedures  • Alert me on articles by topic

Arch Dermatol. 2002;138:1243-1244.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE COSMETIC use of botulinum toxin is now well established. The extended clinical use, multiple publications, and recent Food and Drug Administration (FDA) approval have combined to create this fact, demonstrated in the current media frenzy. But will this situation increase the number of novice injectors and hence increase the incidence of adverse effects, amplifying the "BOTOX backlash" that we are seeing? Will we now see a rash of eyelid and eyebrow ptosis? An epidemic of paralyzed and patulous perioral and cervical muscles? BOTOX losing its shiny reputation as the New Age wonder drug due to an epidemic of avoidable complications? An example of what can happen comes from the scientific basis of the FDA approval. Presumably, the manufacturers of BOTOX (Allergan, Inc, Irvine, Calif) selected physicians they believed were experienced in the cosmetic use of botulinum toxin to perform the FDA studies. And yet, one half of the study . . . [Full Text of this Article]

RELATED ARTICLE

Botulinum A Exotoxin for Hyperfunctional Facial Lines: Where Not to Inject
Murad Alam, Jeffrey S. Dover, Arnold W. Klein, and Kenneth A. Arndt
Arch Dermatol. 2002;138(9):1180-1185.
EXTRACT | FULL TEXT